Brief: Soligenix - Increases Maximum Offering Under Sales Agreement By $2.96 Million
Brief: Soligenix Announces Recent Updates And First Quarter 2026 Financial Results
Soligenix Q1 net loss narrows on lower expenses
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Brief: Soligenix Announces Recent Accomplishments And Year End 2025 Financial Results
Brief: Soligenix Enters Sales Agreement With Rodman
Brief: Positive Clinical Results From Phase 2 Trial Of Sgx945
Brief: Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302
Brief: Soligenix Achieves Enrollment Milestone For Planned Interim Analysis In Confirmatory Phase 3 Clinical Trial Of HyBryte For Treatment Of Cutaneous T-Cell Lymphoma
Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends
Brief: Soligenix Achieves Important Safety Milestone In Its Confirmatory Phase 3 Clinical Trial Of Hybryte™ For The Treatment Of Cutaneous T-Cell Lymphoma
Brief: Soligenix Says On Sept 25, Entered Securities Purchase Agreement With Investors - SEC Filing
Brief: Soligenix Announces Closing Of $7.5 Million Public Offering
Brief: Soligenix Announces Pricing of $7.5 Million Public Offering
Brief: Soligenix Announces Publication Describing Long-Term High Temperature Stability Of Protein Subunit Vaccines For Ebola And Related Viruses
U.S. STOCKS ON THE MOVE-Soho House, Cogent Communications, Beyond
U.S. STOCKS ON THE MOVE-Soligenix, BioXcel, GoodRx
Soligenix jumps on FDA's orphan drug tag for Behcet's disease therapy